Melanoma Dispatch
Follow
Find tag "T-VEC"
2.3K views | +0 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO | Melanoma Dispatch | Scoop.it

"Amgen today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago."


Editor's note: This article describes promising results for a melanoma treatment called talimogene laherparepvec (T-VEC), an immunotherapy that boosts a patient's own immune system to fight cancer. Previous testing of the drug has found mixed results.

Cancer Commons's insight:

MarketWatch  |  Jun 2, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Amgen Vaccine Triggers Immune Response in Advanced Melanoma -Study

"An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

"The vaccine shrank tumors that were directly injected with the drug and tumors around the body that were not injected, according to the data.

"The drug, talimogene laherparepvec, also known as T-vec, is an engineered virus designed to replicate inside the injected tumor, killing cancer cells there, as well as prime the immune system to attack other cancer cells around body."

Cancer Commons's insight:

Reuters  |  Mar 14, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Anti-Melanoma Vaccine May Extend Life

Anti-Melanoma Vaccine May Extend Life | Melanoma Dispatch | Scoop.it

Results of a late-stage clinical trial suggest that an experimental immunotherapy may boost survival in people with melanoma. Called talimogene laherparepvec (T-VEC), the vaccine includes a gene called granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system. The researchers found that people injected with T-VEC lived an average of 4 months longer than those treated with GM-CSF on its own (23 vs 19 mo). In addition, T-VEC made more tumors disappear or shrink by at least half.

Cancer Commons's insight:

Amgen│Nov 18, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial | Melanoma Dispatch | Scoop.it

Researchers report that a modified cold sore virus may help deliver longer lasting shrinkage of melanoma tumors. Called talimogene laherparepvec (T-VEC), the engineered virus kills cancer cells directly and boosts the immune response against them by tagging their surfaces with a protein called granulocyte macrophage colony-stimulating factor (GM-CSF). T-VEC outperformed GM-CSF (administered directly) in a phase III trial of 436 people with melanomas that had spread—tumors shrank more often (26% vs 6%) and were more likely to stay shrunk for at least 6 months (16% vs 2%). The researchers caution that while promising, T-VEC is unlikely to be a stand-alone treatment and suggest that this virus might ultimately be combined with another immunotherapy such as ipilimumab.

Cancer Commons's insight:

ASCO Daily News│Jun 3, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

UPDATE 1-Amgen Melanoma Drug Fails to Improve Overall Survival Rates

"Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.


"The company said the drug met the study's main goal of shrinking tumors, as it had previously reported, but did not meet the secondary goal of improving overall survival in patients with melanoma."


Editor's note: Earlier results from this trial showed that the drug (called T-Vec) improved "progression free survival," which refers to the length of time before a patient's tumor begins growing again. Now, T-Vec has been shown not to affect overall survival times.

Cancer Commons's insight:

Reuters  |  Apr 4, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

T-VEC Keeps Shrinking Melanomas

An experimental vaccine that is injected into melanomas can shrink them for an average of 8 months, according to findings presented at the American Society of Clinical Oncology's 2013 meeting. Called talimogene laherparepvec (T-VEC), this immunotherapy consists of a virus engineered to carry human genes for granulocyte macrophage colony-stimulating growth factor (GM-CSF). Once inside a tumor, T-VEC kills tumor cells both by bursting them and by boosting the immune response against them. In a phase III clinical trial, melanomas shrank in 16% of those injected with T-VEC (48 out of 295) compared to just 2% of those treated directly with GM-CSF (30 out of 141). Moreover, melanomas disappeared completely in more than 10% of those treated with T-VEC. Doctors caution that because T-VEC is injected into melanomas, this treatment is only practical for people with accessible tumors.

Cancer Commons's insight:

Clinical Oncology News  |  Dec  2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Virus Shrinks Melanomas by Bursting Cells

Virus Shrinks Melanomas by Bursting Cells | Melanoma Dispatch | Scoop.it

A cancer-killing virus may shrink melanomas in people, according to new results from an ongoing clinical trial presented at the 2013 European Cancer Congress in Amsterdam, Netherlands. The virus—called talimogene laherparepvec or T-VEC—is injected into tumors, where it divides until the cells pop. The phase III trial has more than 400 people with melanoma; T-VEC shrank tumors in nearly one-third of them. Moreover, tumors didn't grow again for at least 9 months in two-thirds of those who responded to the virus. That said, 26% of those treated with T-VEC had serious side effects including fevers and bacterial skin infections.

Cancer Commons's insight:

StreetInsider.com│Sep 30, 2013

more...
No comment yet.